Free Trial

Augmedix (AUGX) Stock Price, News & Analysis

-0.05 (-4.27%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
491,184 shs
Average Volume
570,851 shs
Market Capitalization
$54.85 million
P/E Ratio
Dividend Yield
Price Target

Augmedix MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
246.0% Upside
$3.88 Price Target
Short Interest
3.84% of Float Sold Short
Dividend Strength
News Sentiment
0.13mentions of Augmedix in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1.02 M Sold Last Quarter
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

550th out of 915 stocks

Business Services, Not Elsewhere Classified Industry

64th out of 86 stocks

AUGX stock logo

About Augmedix Stock (NASDAQ:AUGX)

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

AUGX Stock Price History

AUGX Stock News Headlines

Augmedix (NASDAQ:AUGX) Downgraded by Maxim Group to "Hold"
Augmedix (NASDAQ:AUGX) Stock Rating Lowered by Evercore ISI
Augmedix (NASDAQ:AUGX) PT Lowered to $3.50
Why Is Augmedix (AUGX) Stock Down 41% Today?
Analyst Ratings For Augmedix
See More Headlines
Receive AUGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Business services, not elsewhere classified
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$44.85 million
Book Value
$0.36 per share


Free Float
Market Cap
$54.85 million
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Emmanuel Krakaris (Age 65)
    President, CEO, Secretary & Director
    Comp: $734.33k
  • Mr. Ian Shakil (Age 39)
    Founder, Chief Strategy Officer & Director
  • Ms. Sandra Breber (Age 66)
    Chief Operating Officer
    Comp: $446.05k
  • Mr. Saurav Chatterjee Ph.D. (Age 52)
    Chief Technology Officer
    Comp: $438.05k
  • Mr. Paul Louis Ginocchio (Age 54)
    Chief Financial Officer
  • Todd Holvick
    Head of Legal & Compliance
  • Lia Wallick
    Head of People
  • Dr. Davin Lundquist M.D.
    Chief Medical Officer
  • Mr. Jonathan Hawkins (Age 54)
    Chief Revenue Officer
    Comp: $417.71k
  • Mr. Tomer Levy
    Senior Vice President of Engineering

AUGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Augmedix stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Augmedix in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AUGX shares.
View AUGX analyst ratings
or view top-rated stocks.

What is Augmedix's stock price target for 2024?

3 Wall Street analysts have issued 1 year price objectives for Augmedix's shares. Their AUGX share price targets range from $1.50 to $5.50. On average, they anticipate the company's share price to reach $3.88 in the next twelve months. This suggests a possible upside of 246.0% from the stock's current price.
View analysts price targets for AUGX
or view top-rated stocks among Wall Street analysts.

How have AUGX shares performed in 2024?

Augmedix's stock was trading at $5.85 on January 1st, 2024. Since then, AUGX shares have decreased by 80.9% and is now trading at $1.12.
View the best growth stocks for 2024 here

When is Augmedix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our AUGX earnings forecast

How were Augmedix's earnings last quarter?

Augmedix, Inc. (NASDAQ:AUGX) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.09) earnings per share for the quarter. The business earned $12.68 million during the quarter, compared to the consensus estimate of $12.30 million. Augmedix had a negative net margin of 41.95% and a negative trailing twelve-month return on equity of 178.34%.

What guidance has Augmedix issued on next quarter's earnings?

Augmedix updated its FY 2024 earnings guidance on Monday, May, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $52.0 million-$55.0 million, compared to the consensus revenue estimate of $61.2 million.

When did Augmedix IPO?

Augmedix (AUGX) raised $40 million in an IPO on Tuesday, October 26th 2021. The company issued 10,000,000 shares at a price of $4.00 per share. William Blair, B. Riley Securities, Benchmark and Lake Street acted as the underwriters for the IPO.

Who are Augmedix's major shareholders?

Augmedix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (2.98%), Vanguard Group Inc. (2.66%), Russell Investments Group Ltd. (1.34%), Essex Investment Management Co. LLC (1.08%), Hood River Capital Management LLC (1.00%) and Ancora Advisors LLC (0.91%). Insiders that own company stock include Emmanuel Krakaris, Ian Shakil, Paul Ginocchio and Saurav Chatterjee.
View institutional ownership trends

How do I buy shares of Augmedix?

Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUGX) was last updated on 5/23/2024 by Staff

From Our Partners